Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

AbbVie's Subcutaneous Skyrizi Shows Endoscopic Benefits In Crohn's Diseases

(RTTNews) - Tuesday, AbbVie reported new Phase 3 AFFIRM data showcasing endoscopic outcomes with subcutaneous Skyrizi in adults with moderately to severely active Crohn's disease.

We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.

Read the original at nasdaq.com →

More in Health & Medicine

More from Wednesday 14 October →